1. Home
  2. ACRS vs ATGL Comparison

ACRS vs ATGL Comparison

Compare ACRS & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.50

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

N/A

Current Price

$16.60

Market Cap

286.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
ATGL
Founded
2012
2017
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
286.4M
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
ACRS
ATGL
Price
$3.50
$16.60
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
2.5M
2.1K
Earning Date
05-07-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$9.01
52 Week High
$4.89
$50.00

Technical Indicators

Market Signals
Indicator
ACRS
ATGL
Relative Strength Index (RSI) 50.91 43.98
Support Level $2.67 $15.23
Resistance Level $3.86 $20.25
Average True Range (ATR) 0.26 0.93
MACD -0.01 0.11
Stochastic Oscillator 46.32 32.52

Price Performance

Historical Comparison
ACRS
ATGL

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: